Synthetic biology aims to make biology easier to engineer and to program. Thanks to advances in computing power, the ability to make long tracts of DNA, new tools like CRISPR that can be used to edit genomes, and the enthusiasm of young scientists and even amateurs who want to enter the field, synthetic biology is poised to change the future of medicine, agriculture, and manufacturing. Yet, while this new field promises vast opportunities and benefits, there are also risks. There are biosecurity risks that these technologies will be deliberately used for harm; safety risks to people and the environment; ethical and social considerations for how to apply these technologies; and there are risks to the competitiveness of nations that do not invest in these technologies that are likely to spur economic growth. This volume is dedicated to a discussion of what can be done to minimize risks and maximize the benefits of synthetic biology. Praise for Synthetic Biology: Safety, Security, and Promise "There can be no doubt that advances in the life sciences, including new insights and tools provided by synthetic biology, place us in a position to create exciting and novel products and approaches for patients in need. Gigi Gronvall describes that promise but also lays forth critical policy concerns that need to be addressed so that we don't risk safety, security, or the competitiveness of US science." - Margaret Hamburg, MD, Former FDA Commissioner and Foreign Secretary, National Academy of Medicine "Synthetic biology gives us tools that can help tackle global problems that affect humanity-but for that to happen, the risks of bioterror or bio-error need to be dealt with and managed, as well. Gronvall clearly describes the policy challenges that must be addressed and concludes with steps to enhance US leadership and competitiveness in the global bio-economy." - J. Craig Venter, PhD, founder, chairman, and CEO of the J. Craig Venter Institute and co-founder, executive chairman and co-chief scientist of Synthetic Genomics, Inc. "For those of us working in the lab, it is important to embrace conversations with those who aren't - including strategies for biological security, to create new synthetic biology products - with respect for facts about GMO risk/benefit balances, creating a culture of safe lab practices and norms worldwide. Gigi Gronvall dissects such issues at stake in synthetic biology and presents a pragmatic and scientifically responsive path forward for anyone in a position to influence, regulate, decide upon, or benefit from the science to follow." - George Church, PhD, Professor of Genetics Harvard Medical School and Director of PersonalGenomes.org "Synthetic biology presents some of the greatest challenges and opportunities of the 21st Century. Gigi Gronvall navigates a path to follow, to make sure risks are addressed and opportunities are not squandered. It should be read by all concerned about national security." - The Honorable Andrew Weber, head of global partnerships for Metabiota and former Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs
Author Biography:
Dr. Gigi Kwik Gronvall is a Senior Associate at the Johns Hopkins Center for Health Security and visiting faculty at the Johns Hopkins Bloomberg School of Public Health. She is an immunologist by training. Dr. Gronvall's work focuses on the role of scientists in health security-how they can contribute to an effective technical response against a biological weapon or a natural epidemic. She is the author of Preparing for Bioterrorism: The Alfred P. Sloan Foundation's Leadership in Biosecurity. By describing the major grants that represented Sloan's investments in civilian preparedness, public health law, law enforcement, air filtering in buildings, influenza preparedness, and business preparedness, Dr. Gronvall constructed a chronicle of early gains in US efforts to confront the threat of bioterrorism, for a nontechnical audience. Dr. Gronvall is a member of the Threat Reduction Advisory Committee (TRAC), which provides the Secretary of Defense with independent advice and recommendations on reducing the risk to the United States, its military forces, and its allies and partners posed by nuclear, biological, chemical, and conventional threats. She served as the Science Advisor for the Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism from April 2009 until the Commission ended in February 2010. She has testified before Congress about the safety and security of high-containment biological laboratories in the United States and served on several task forces related to laboratory and pathogen security, most recently the National Institutes of Health Blue Ribbon Panel to Review the 2014 Variola Virus Incident on the NIH Campus (2016) and the Committee for Comprehensive Review of DoD Laboratory Procedures, Processes, and Protocols Associated with Inactivating Bacillus anthracis Spores, formed in response to the Dugway anthrax shipments (2015). Dr. Gronvall has investigated and presented policy recommendations on the governance of science to the Biological Weapons Convention (BWC) in Geneva, Switzerland. She was a National Research Council Postdoctoral Associate at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) in Fort Detrick, Maryland. Dr. Gronvall received a BS in biology from Indiana University, Bloomington. She subsequently worked as a protein chemist at the Memorial Sloan-Kettering Cancer Center and received a PhD from Johns Hopkins University.
